

In the recent meeting, several key topics were addressed, including board resignations, regulatory participation, public meeting considerations, and the importance of collecting use cases to inform AI implementation. The session also emphasized the need for regulatory compliance and stakeholder perspectives in shaping the group's activities.

Board Resignations

The meeting opened with the announcement of board resignations. Two federal representatives resigned to avoid potential conflicts of interest with HHS efforts in AI.

Industry and Regulatory Reassurance

Despite the resignations, reassurance was given that the Office of the National Coordinator for Health Information Technology (ONC) continues to support the group's efforts. ONC's participation and guidance remain steadfast, with staff actively involved in the work groups. The Food and Drug Administration (FDA) also confirmed its ongoing involvement, providing feedback and ensuring continued collaboration with regulatory bodies.

Public Meeting Considerations

A proposal to make meetings public was discussed. The workgroup discussed methods to engage the community, and workgroup members agreed on Chatham House summaries communicated publicly via newsletters and opportunities to solicit public feedback. This approach aims to balance productive working spaces with transparency and public engagement.

Use Case Collection

The ongoing effort to collect use cases from participants was highlighted. This initiative is critical for guiding the group's focus and planning next steps. By gathering real-world AI applications, the group aims to address AI implementation challenges effectively. The structured approach ensures that activities align with participants' diverse needs and the practical aspects of AI deployment.

Stakeholder Perspectives

The importance of considering individual personas in the analysis was emphasized. A persona-based approach helps address the unique perspectives and requirements of different stakeholders. This method acknowledges the diverse challenges faced by stakeholders and incorporates these varied perspectives into the group's analytical framework. The scope and time frame to address all use cases were also discussed, highlighting the complexity of this task.

Regulatory Compliance

The urgency for clinically pragmatic interpretations of AI regulations was stressed. Clear, actionable guidance is needed to help health systems remain compliant while rapidly deploying AI solutions. This discussion underscored the necessity of providing resources that health systems can practically apply to navigate the regulatory landscape effectively.

Follow-Up Tasks

- **Use Cases:** Collect detailed use cases from members to stress test the assurance standards checklist.
- **Feedback on Assurance Standards Checklist:** Invite members to provide feedback through testing the checklist.

Overall, the meeting underscored the importance of proactive measures to avoid conflicts of interest, maintaining robust regulatory participation, and balancing transparency with effective working processes. The collection of use cases and a focus on regulatory compliance remain pivotal for the group's success in advancing AI implementation.



@CHAI_nonprofit



www.chai.org



admin@chai.org



[LinkedIn](#)